Volume 16 Supplement 1

Abstracts from the 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications

Open Access

C-type natriuretic peptide/guanylyl cyclase-B (GC-B) system attenuates proliferation of rhabdomyosarcoma in combination with sildenafil: A novel anticancer therapy

  • Masahiro Zenitani1, 2Email author,
  • Shuichiro Uehara2,
  • Toru Kimura1,
  • Takashi Nojiri1,
  • Koichi Miura1,
  • Hiroshi Hosoda3,
  • Mikiya Miyazato1,
  • Hiroomi Okuyama2 and
  • Kenji Kangawa1
BMC Pharmacology and Toxicology201516(Suppl 1):A103

DOI: 10.1186/2050-6511-16-S1-A103

Published: 2 September 2015

Background/purpose

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Since patients with high-risk RMS have limited treatment options and a poor prognosis, and late complications including growth disturbance and secondary cancer induced by chemotherapy or radiation therapy are essential problems, novel therapies are urgently needed. C-type natriuretic peptide (CNP) has physiological activity mainly for mesenchymal cells to inhibit cell proliferation. We hypothesized that CNP attenuates proliferation of human RMS, a malignant mesenchymal tumor and provide rationale for using CNP to treat RMS.

Experimental design

Gene expression of guanylyl cyclase B (GC-B), receptor of the CNP in rhabdomyosarcoma clinical samples and cell lines was assessed by using quantitative polymerase chain reaction. To ascertain biological activity of CNP in RMS cells, cyclic guanosine monophosphate (cGMP), the second messenger molecule which is produced by the activation of GC-B and serves as the major signaling molecule was measured following addition of CNP. However, cGMP is quickly degraded by phosphodiesterases and thereby biological activity becomes deactivated. Therefore, sildenafil, a selective inhibitor of phosphodiesterase 5 (PDE5) was added to CNP to prolong or enhance the effects of physiological processes mediated by cGMP by inhibiting its degradation. The in vitro and in vivo efficacy of CNP and sildenafil was evaluated alone and in combination.

Results

GC-B expression was seen in all alveolar and embryonal clinical samples which had higher GC-B expression than RMS cell lines. Since RD and RMS-YM cell lines had considerably lower GC-B expression than the clinical samples and KYM-1 and RH30 had no detectable expression, GC-B stable expression cell lines, RD-GC-B was established to mimic the clinical samples. CNP increased the rate of cGMP accumulation in RMS cells depending on concentration of this peptide. Combinations of CNP and sildenafil synergistically inhibited cell growth of RD-GC-B cells by inhibiting extracellular-signal-regulated kinase (Erk), the major signal for cell proliferation in RMS. The synergistic effect on growth and reduction of phosphorylated Erk as tumor pharmacodynamic biomarker were also confirmed in a mouse xenograft model.

Conclusions

These results suggest that CNP in combination with sildenafil may have clinical efficacy for treating RMS patients.

Authors’ Affiliations

(1)
Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute
(2)
Department of Pediatric Surgery, Osaka University Graduate School of Medicine
(3)
Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center Research Institute

Copyright

© Zenitani et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement